Objective To investigate the relationship between CRP,
plasminogen activator inhibitor type 1 (
PAI-1) levels,
PAI-1 gene promoter 4G/5G polymorphism and the type of acute
myocardial infarction (
ST elevation myocardial infarction,
STEMI vs the non-
ST elevation Myocardial infarction,
NSTEMI).
Methods One hundred seventy-six consecutive
patients with AMI were included for the study, of whom 60 had
STEMI and 56 had
NSTEMI, and 60
adults without cardiovascular and
cerebrovascular disease were selected as controls.
Blood samples were obtained from
patients within 6 h of AMI and the
plasma PAI-1, CRP, and the
gene polymorphism were measured. Results
Plasma levels of
PAI-1 and CRP were higher in AMI groups, compared those in the
control group, and
plasma levels of
PAI-1 were significantly higher in
patients with
STEMI compared to those with
NSTEMI (80.12ng/ml VS.73.01ng/ml, P 0.05).
PAI-1 levels presented a significant correlation with CRP levels in the
NSTEMI subjects. However,
PAI-1 and CRP levels could explain the lack of a significant relationship between them in control and
STEMI subjects.The frequencies of 4G/4G
genotype in the AMI group were higher than those in the
control group and higher in
patient with
STEMI than in
patient with
NSTEMI.
Plasma levels of
PAI-1 in subjects with 4G/4G
genotype were significantly increased as compared to those in subjects with 4G/5G and 5G/5G
genotype. Conclusions
Plasma PAI-1 levels were associated with different
myocardial infarction type, and
PAI-1 promoter 4G/5G polymorphisms and CRP may be related to
plasma PAI-1 levels.